BioSpace News Archive

Policy

FDA Creates Adcomm for Genetic Metabolic Diseases and Potential Treatments

Ahead of an expected surge in regulatory filings, the FDA is establishing the Genetic Metabolic Diseases Advisory Committee to provide advice on treatments for these complex and challenging conditions.

December 13, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Vertex Non-Opioid Pain Candidate Shows Promising Phase II Results

The company’s non-opioid painkiller candidate VX-548 decreased Numerical Pain Rating Scale scores by at least two points after 12 weeks in a mid-stage diabetic peripheral neuropathy study.

December 13, 2023
·
2 min read
·
Tristan Manalac
Headed to JPM? Here Are Some Tips to Make the Most of It

BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.

December 13, 2023
·
3 min read
·
Tyler Patchen
Policy

Oncologists Defend CAR-T After FDA Advisory

The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.

December 13, 2023
·
6 min read
·
Jill Neimark
Career Advice

How to Prepare for a Job Interview

Preparation is key to ensuring one stands out in an increasingly competitive job market. We asked an expert for tips.

December 13, 2023
·
3 min read
·
Sanjukta Mondal
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.

December 13, 2023
·
1 min read
·
Tyler Patchen
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

December 13, 2023
·
1 min read
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Pharming Group N.V. announces the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies beyond activated phosphoinositide 3-kinase delta syndrome.

December 13, 2023
·
8 min read
MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

MitoRx Therapeutics announces the final close of its seed extension financing round, with £4m raised to date from existing investors.

December 13, 2023
·
4 min read
Drug Development

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04

Levicept Ltd announces it has completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent.

December 13, 2023
·
3 min read